| Project/Area Number |
13671742
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
MAEDA Hiroo Saitama Medical School, Medical School, Professor, 医学部, 教授 (30134597)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKUBO Mitsuo Saitama Medical School, Medical School, Assistant professor, 医学部, 講師 (40260781)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,600,000 (Direct Cost: ¥3,600,000)
Fiscal Year 2003: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 2002: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | Ovarian cancer / T cell / IL-4 / Cell therapy / 細胞治療 |
|---|
| Research Abstract |
Peripheral blood stem cell transplantation (PBSCT) combined with chemotherapy for the patients with advanced ovarian cancer is an effective therapy but not a perfect one. Therefore, it is necessary to develop novel cell therapies followed this chemotherapy with PBSCT, in order to improve long term survival.
At first we confirmed that the peripheral blood of the patients after anti-cancer chemotherapy possessed enough number of CD4 positive memory T cells. Next, we surveyed ovarian cancer-related antigen : CA125, to detect antigenic amino acid sequences in it. Among 48 of twenty amino acid residues analogue peptides, two kinds of sequences were able to activate CD4 positive T cells form the patients with ovarian cancer. In 25 samples of peripheral blood mononuclear cells, IL-4 and/or IFNγ were detected from 84% of the samples.
From these results, it is possible to acquire cell therapeutic effects by CA125 analogue peptide-activated CD4 positive T cell for the patients followed chemotherapy with PBSCT.
|
